Results 291 to 300 of about 251,978 (341)

Model‐Informed Drug Development for Ligelizumab in Patients With Chronic Spontaneous Urticaria

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Model‐informed drug development (MIDD) has been increasingly applied to guide decision‐making, ameliorate efficiency, and enhance the likelihood of successful trials. The development of ligelizumab, a humanized anti‐IgE monoclonal antibody, in chronic spontaneous urticaria (CSU) illustrated how MIDD can be applied to support central aspects of
Andrzej Bienczak, Aurelie Gautier, Eva Hua, Yan Ji, Emil Scosyrev, Serge Smeets, Thomas Severin, Anton Drollmann, Manmath Patekar, Marina Savelieva   +9 more
wiley   +1 more source

Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients-exploratory results from TITAN-RCC. [PDF]

ESMO Open
Fritzsch A, Leucht K, Röber N, Conrad K, Rothe R, Wehner R, Schumacher U, Esteban E, Barthélémy P, Schmidinger M, Schmitz M, Grimm MO.   +11 more
europepmc   +1 more source

Association between circulating thyroperoxidase (TPO), anti-TPO IgE, anti-TPO IgG, and different clinical outcomes in chronic urticaria: A hypothesis-generating study. [PDF]

World Allergy Organ J
Lopez JF, Bedoya V, Arango JC, Naranjo TW, Garcia E, Sanchez J.   +5 more
europepmc   +1 more source

Unilateral Facial Swelling as the Inaugural Sign of Anti-NPX2 Dermatomyositis: A Diagnostic Challenge in Oral Medicine. [PDF]

Case Rep Dent
Tilotta F, Le Vayer H, Bory O, Morbieu C, Radoi L.   +4 more
europepmc   +1 more source

Protein Array Technology Identifies Rituximab-Treated Non-Responder Rheumatoid Arthritis Patients to Generate New Autoantibody Repertoires during Treatment

, 2017
Zoltán Konthur, M.M. Wiemkes, Thomas Häupl, G. R. Burmester, Karl Skriner   +4 more
openalex   +1 more source

Autoimmune neuropsychiatric disorders manifesting with psychosis. [PDF]

J Clin Invest
Cabrera-Maqueda JM, Planagumà J, Guasp M, Dalmau J.   +3 more
europepmc   +1 more source

Figure S1 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma

Rongrong Luo, Pei Zhong, Xiying Li, Juan Cai, Yimin Tao, Bangzhu Xiong, Hancheng Zheng, Zhishang Zhang, Le Tang, Jiarui Yao, Yingrui Li, Yuankai Shi, Xiaohong Han   +12 more
openalex   +1 more source

Autoimmune reactions to ACE2 triggered by SARS-CoV-2 S protein and their histopathological consequences. [PDF]

Sci Rep
Beduleva L, Fomina K, Khramova T, Terentiev A, Menshikova D, Terentieva O, Menshikov I, Sidorov A, Makhankova P, Abisheva N.   +9 more
europepmc   +1 more source

Therapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathology. [PDF]

Proc Natl Acad Sci U S A
Bayer AC, Sanmarco LM, Pellerin A, Masi G, Plasencia A, Anderson JM, Nowak RJ, Damato V, Massacesi L, Pham MC, Khani-Habibabadi F, Vital H, Higginson-Scott N, Otipoby KL, Xing Y, Mascanfroni ID, O'Connor KC.   +16 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Thyroid autoantibodies

Journal of Clinical Pathology, 2022
Thyroid-stimulating hormone (TSH) receptor antibody (TSH-R-Ab or TRAb) testing plays a pivotal role in arriving at the aetiological diagnosis in patients with thyrotoxicosis. A positive test establishes the diagnosis of Graves’ disease (GD) while a negative result in conjunction with imaging studies supports other possible aetiologies. In patients with
Shivangi Nikhil Dwivedi, Tejas Kalaria, Harit Buch   +2 more
openaire   +2 more sources